Profound Medical Corp. 8-K

What Happened

• On July 24, 2026, Profound Medical Corp. announced new data from the Level 1 post‑market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy. The company furnished a press release describing the data as Exhibit 99.1 to its Form 8‑K filing under Regulation FD.

Key Details

• Filing date: July 24, 2026 (Current Report on Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Trial: Level 1 post‑market CAPTAIN randomized controlled trial comparing TULSA Procedure vs. robotic radical prostatectomy.
• Disclosure: Press release announcing the data is attached as Exhibit 99.1 to the 8‑K.
• Signatory: Report signed by Rashed Dewan, Chief Financial Officer of Profound Medical Corp.

Why It Matters

• The company publicly disclosed new randomized clinical data comparing its TULSA thermal therapy to a common surgical alternative, which is a material operational development for a medical device company. Investors should review the press release (Exhibit 99.1) for the specific clinical outcomes and metrics, since trial results can affect product adoption, competitive positioning, reimbursement discussions, and future revenue prospects. This 8‑K is a Regulation FD disclosure, signaling the company intends the information for broad investor distribution.